AEON Biopharma Completes BPD Type 2a Meeting with FDA; Expects Proceeds from PIPE Financing and Note Exchange

AEON Biopharma has completed a BPD Type 2a meeting with the FDA for its biosimilar ABP-450, which is a therapeutic use of the same molecule as cosmetic product Jeuveau. The meeting represents a procedural milestone, and the company expects to receive meeting minutes within 30 days. In parallel, AEON has secured shareholder approval for the exchange of convertible notes held by Daewoong Pharmaceutical, which is expected to reduce the company's outstanding debt and simplify its capital structure.